The DOI matches its Crossref record.
Treatment of Estrogen Receptor-Positive Breast Cancer
Abstract
Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine therapy (ET), and approximately 70% of human breast cancers (BCs) are hormone-dependent and ER-positive. The introduction of adjuvant systemic therapy led to a significant improvement in post-surgical survival and a reduction in disease relapse, especially in women with early BC and those with ER+ tumors, who may receive ET alone or in combination with cytotoxic therapy. Adjuvant ET currently consists of (i) ovarian suppression, (ii) selective estrogen receptor modulators (SERMs) and down-regulators, and (iii) aromatase inhibitors (AIs). In patients with ER+ tumors pharmacologic ovary suppression with gonadotropin-releasing hormone agonists in combination with standard adjuvant therapy is generally more effective than adjuvant chemotherapy alone. Tamoxifen is the best established SERM, has favorable effects on BC control and bone metabolism, but also has adverse effects due to its estrogenic activity in other tissues. For these reasons, other SERMs have been developed. Fulvestrant is an ER down-regulator with several potential advantages over SERMs, including a 100-fold increase in its affinity for ER compared with tamoxifen and no estrogen-like activity in the uterus. The inhibition of the aromatase system with third-generation AIs is associated with improved survival in patients with advanced BC compared with SERMs. In postmenopausal patients with ER+ BC adjuvant treatment with AIs should be performed, either as sequential treatment after tamoxifen or as upfront therapy. Studies evaluating the role of AIs as first-line therapy are ongoing and the results are encouraging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M. R., Hosseini-Fard, S. R., Babolhavaeji, K., Khani Ali Akbari, S., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 394
Environmental Endocrine-Disrupting Chemical Exposure: Role in Non-Communicable Diseases
Kumar, M., Sarma, D. K., Shubham, S., Kumawat, M., Verma, V., Prakash, A., & Tiwari, R. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.553850 · Cited by 391
Liquid biopsy in breast cancer: A comprehensive review
Alimirzaie, S., Bagherzadeh, M., & Akbari, M. R. (2019) · Clinical Genetics · doi:10.1111/cge.13514 · Cited by 332
Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium
Konkankit, C. C., Marker, S. C., Knopf, K. M., & Wilson, J. J. (2018) · Dalton Transactions · doi:10.1039/c8dt01858h · Cited by 284
Metadata
- Authors
- Lumachi, F., Brunello, A., Maruzzo, M., Basso, U., & Basso, S.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-01-16
- Volume
- 20
- Issue
- 5
- Pages
- 596-604
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W1980861196
- Cited by
- 291
- References
- 0
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Estrogen Receptor-Positive Breast Cancer. https://app.cochat.ai/papers/10.2174/092986713804999303
- The paper
- Lumachi, F., Brunello, A., Maruzzo, M., Basso, U., & Basso, S. (2013). Treatment of Estrogen Receptor-Positive Breast Cancer. Current Medicinal Chemistry. https://doi.org/10.2174/092986713804999303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.